Chongran Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chongran Sun has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Jian Zheng
Department of Neurosurgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
20 shared publications - Qi Xie
Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, Zhejiang, China; School of Life Sciences, Westlake University, Hangzhou 310024, Zhejiang, China
20 shared publications - Chen Guo
Westlake Disease Modeling Laboratory, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China
19 shared publications - Chengfang Sun
Department of Urology, The Second Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China
19 shared publications - Chun Wang
Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
19 shared publications - Fuyi Liu
Department of Neurosurgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
19 shared publications
Latest Publications
- 17 March 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (9) , 1-14
Efficacy of concurrent hyperbaric oxygen therapy with chemoradiotherapy for glioma: a meta-analysis
Objective This study aimed to systematically evaluate the therapeutic efficacy and safety profile of concurrent hyperbaric oxygen therapy (HBOT) as an adjunct to chemoradiotherapy in patients with glioma. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive meta-analysis (PROSPERO registration: CRD420251007610). The search was performed in PubMed, Web of Science, Cochrane, EMBASE, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WanFang (inception to March 2025). Eligible studies were randomized controlled trials (RCTs) assessing tumor response, survival outcomes, quality of life (QoL), and adverse events. Subgroup analyses were performed based on HBOT pressure and session duration. Statistical analysis was performed using Review Manager version 5.3. Results Nine RCTs involving 837 patients with glioma were included. Pooled analyses demonstrated that HBOT significantly enhanced objective tumor response rates (odds ratio [OR] = 3.67, 95% confidence interval [CI] 2.59–5.18; p < 0.00001) and 3 year overall survival (OR = 0.52, 95% CI 0.33–0.82; p = 0.005) when combined with chemoradiotherapy. QoL scores showed marked improvement in HBOT-treated groups (mean difference = 12.33, 95% CI 10.69–13.96; p < 0.00001). Subgroup analyses on tumor response demonstrated consistent benefits across HBOT pressures and durations. Conclusion This meta-analysis provides evidence that concurrent HBOT with chemoradiotherapy may be associated with superior outcomes compared to chemoradiotherapy alone in glioma patients. These findings warrant verification in large-scale, multicenter Phase 3 trials.
- 17 March 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (9) , 1-14
Efficacy of concurrent hyperbaric oxygen therapy with chemoradiotherapy for glioma: a meta-analysis
Objective This study aimed to systematically evaluate the therapeutic efficacy and safety profile of concurrent hyperbaric oxygen therapy (HBOT) as an adjunct to chemoradiotherapy in patients with glioma. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive meta-analysis (PROSPERO registration: CRD420251007610). The search was performed in PubMed, Web of Science, Cochrane, EMBASE, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WanFang (inception to March 2025). Eligible studies were randomized controlled trials (RCTs) assessing tumor response, survival outcomes, quality of life (QoL), and adverse events. Subgroup analyses were performed based on HBOT pressure and session duration. Statistical analysis was performed using Review Manager version 5.3. Results Nine RCTs involving 837 patients with glioma were included. Pooled analyses demonstrated that HBOT significantly enhanced objective tumor response rates (odds ratio [OR] = 3.67, 95% confidence interval [CI] 2.59–5.18; p < 0.00001) and 3 year overall survival (OR = 0.52, 95% CI 0.33–0.82; p = 0.005) when combined with chemoradiotherapy. QoL scores showed marked improvement in HBOT-treated groups (mean difference = 12.33, 95% CI 10.69–13.96; p < 0.00001). Subgroup analyses on tumor response demonstrated consistent benefits across HBOT pressures and durations. Conclusion This meta-analysis provides evidence that concurrent HBOT with chemoradiotherapy may be associated with superior outcomes compared to chemoradiotherapy alone in glioma patients. These findings warrant verification in large-scale, multicenter Phase 3 trials.
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag130
The prognostic role of surgical resection in selected patients with primary CNS lymphoma based on voxel-wise analysis
Surgical resection is controversial in treating primary central nervous system lymphoma (PCNSL). This study aimed to elucidate the prognostic role of resection based on treatment- and survival-related tumor localizations. Magnetic resonance imaging (MRI) data of 122 untreated PCNSL patients from January 2007 to October 2021 were analyzed. Images were registered to a standard anatomical template, followed by lesion segmentation. Analysis of differential involvement (ADIFFI) identified statistically significant voxel-wise clusters using P-value heatmaps. Overall survival (OS) and progression-free survival (PFS) were evaluated via Kaplan-Meier analyses. Multivariate Cox regression was performed to identify independent prognostic factors. Favorable but non-significant trends for OS and PFS were detected in patients receiving resection compared to biopsy. ADIFFI revealed that clusters in superficial frontal and parietal areas were more likely to receive resection, whereas deep-seated clusters were more inclined to be biopsied. Superficial localization also predominated in patients with OS > 2 years, suggesting the spatial confounding effect. Crucially, by controlling for the dual confounders of tumor location and age, significantly prognostic advantages for resection over biopsy were identified in patients with superficial PCNSLs aged ≤ 70 years. Further Cox regression in this subgroup demonstrated that surgical resection, particularly gross total resection, emerged as an independent protective factor for OS. The historically perceived limited benefit of resection in PCNSL may be confounded by tumor localization and patient age. For selected patients with superficial lesions aged ≤ 70 years, resection appears to provide survival advantages, offering a reference to refine surgical decision-making.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag130
Open AccessThe prognostic role of surgical resection in selected patients with primary CNS lymphoma based on voxel-wise analysis
Surgical resection is controversial in treating primary central nervous system lymphoma (PCNSL). This study aimed to elucidate the prognostic role of resection based on treatment- and survival-related tumor localizations. Magnetic resonance imaging (MRI) data of 122 untreated PCNSL patients from January 2007 to October 2021 were analyzed. Images were registered to a standard anatomical template, followed by lesion segmentation. Analysis of differential involvement (ADIFFI) identified statistically significant voxel-wise clusters using P-value heatmaps. Overall survival (OS) and progression-free survival (PFS) were evaluated via Kaplan-Meier analyses. Multivariate Cox regression was performed to identify independent prognostic factors. Favorable but non-significant trends for OS and PFS were detected in patients receiving resection compared to biopsy. ADIFFI revealed that clusters in superficial frontal and parietal areas were more likely to receive resection, whereas deep-seated clusters were more inclined to be biopsied. Superficial localization also predominated in patients with OS > 2 years, suggesting the spatial confounding effect. Crucially, by controlling for the dual confounders of tumor location and age, significantly prognostic advantages for resection over biopsy were identified in patients with superficial PCNSLs aged ≤ 70 years. Further Cox regression in this subgroup demonstrated that surgical resection, particularly gross total resection, emerged as an independent protective factor for OS. The historically perceived limited benefit of resection in PCNSL may be confounded by tumor localization and patient age. For selected patients with superficial lesions aged ≤ 70 years, resection appears to provide survival advantages, offering a reference to refine surgical decision-making.
- Open Access
- 6 August 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1624498
Postoperative microcystic meningioma of the fourth ventricle with subsequent giant cell reparative granuloma: a case report
Background: Microcystic meningioma (MM) is a distinctive benign tumor typically located in the supratentorial region. Giant cell reparative granuloma (GCRG) is another rare reactive benign lesion associated with surgical trauma or tissue injury. The occurrence of MM in the fourth ventricle is extremely uncommon, and the development of GCRG following cranial tumor surgery is rare.Case report: We present a case of MM extending into the fourth ventricle in a 54-year-old man. The initial diagnosis was based on magnetic resonance imaging (MRI), and the tumor was successfully treated with surgery. Postoperative histopathological analysis confirmed the diagnosis of MM. However, a mass was detected at the original surgical site during a follow-up examination one year later. Combined preoperative imaging and postoperative pathology confirmed the final diagnosis of giant cell reparative granuloma (GCRG).Conclusion: In cases of MM at atypical locations and GCRG, an imaging-based differential diagnosis is crucial for guiding treatment decisions and predicting prognosis. Regular postoperative reviews are also essential for detecting complications.
- 6 August 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1624498
Open AccessPostoperative microcystic meningioma of the fourth ventricle with subsequent giant cell reparative granuloma: a case report
Background: Microcystic meningioma (MM) is a distinctive benign tumor typically located in the supratentorial region. Giant cell reparative granuloma (GCRG) is another rare reactive benign lesion associated with surgical trauma or tissue injury. The occurrence of MM in the fourth ventricle is extremely uncommon, and the development of GCRG following cranial tumor surgery is rare.Case report: We present a case of MM extending into the fourth ventricle in a 54-year-old man. The initial diagnosis was based on magnetic resonance imaging (MRI), and the tumor was successfully treated with surgery. Postoperative histopathological analysis confirmed the diagnosis of MM. However, a mass was detected at the original surgical site during a follow-up examination one year later. Combined preoperative imaging and postoperative pathology confirmed the final diagnosis of giant cell reparative granuloma (GCRG).Conclusion: In cases of MM at atypical locations and GCRG, an imaging-based differential diagnosis is crucial for guiding treatment decisions and predicting prognosis. Regular postoperative reviews are also essential for detecting complications.
- Open Access
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary table 2 from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
Supplementary table 2 from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 2 from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
Supplementary table 2 from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
- Open Access
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
Isocitrate dehydrogenase (IDH)–wild-type (WT) high-grade gliomas, especially glioblastomas, are highly aggressive and have an immunosuppressive tumor microenvironment. Although tumor-infiltrating immune cells are known to play a critical role in glioma genesis, their heterogeneity and intercellular interactions remain poorly understood. In this study, we constructed a single-cell transcriptome landscape of immune cells from tumor tissue and matching peripheral blood mononuclear cells (PBMC) from IDH-WT high-grade glioma patients. Our analysis identified two subsets of tumor-associated macrophages (TAM) in tumors with the highest protumorigenesis signatures, highlighting their potential role in glioma progression. We also investigated the T-cell trajectory and identified the aryl hydrocarbon receptor (AHR) as a regulator of T-cell dysfunction, providing a potential target for glioma immunotherapy. We further demonstrated that knockout of AHR decreased chimeric antigen receptor (CAR) T-cell exhaustion and improved CAR T-cell antitumor efficacy both in vitro and in vivo. Finally, we explored intercellular communication mediated by ligand–receptor interactions within the tumor microenvironment and PBMCs and revealed the unique cellular interactions present in the tumor microenvironment. Taken together, our study provides a comprehensive immune landscape of IDH-WT high-grade gliomas and offers potential drug targets for glioma immunotherapy.
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
Isocitrate dehydrogenase (IDH)–wild-type (WT) high-grade gliomas, especially glioblastomas, are highly aggressive and have an immunosuppressive tumor microenvironment. Although tumor-infiltrating immune cells are known to play a critical role in glioma genesis, their heterogeneity and intercellular interactions remain poorly understood. In this study, we constructed a single-cell transcriptome landscape of immune cells from tumor tissue and matching peripheral blood mononuclear cells (PBMC) from IDH-WT high-grade glioma patients. Our analysis identified two subsets of tumor-associated macrophages (TAM) in tumors with the highest protumorigenesis signatures, highlighting their potential role in glioma progression. We also investigated the T-cell trajectory and identified the aryl hydrocarbon receptor (AHR) as a regulator of T-cell dysfunction, providing a potential target for glioma immunotherapy. We further demonstrated that knockout of AHR decreased chimeric antigen receptor (CAR) T-cell exhaustion and improved CAR T-cell antitumor efficacy both in vitro and in vivo. Finally, we explored intercellular communication mediated by ligand–receptor interactions within the tumor microenvironment and PBMCs and revealed the unique cellular interactions present in the tumor microenvironment. Taken together, our study provides a comprehensive immune landscape of IDH-WT high-grade gliomas and offers potential drug targets for glioma immunotherapy.
- Open Access
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
Isocitrate dehydrogenase (IDH)–wild-type (WT) high-grade gliomas, especially glioblastomas, are highly aggressive and have an immunosuppressive tumor microenvironment. Although tumor-infiltrating immune cells are known to play a critical role in glioma genesis, their heterogeneity and intercellular interactions remain poorly understood. In this study, we constructed a single-cell transcriptome landscape of immune cells from tumor tissue and matching peripheral blood mononuclear cells (PBMC) from IDH-WT high-grade glioma patients. Our analysis identified two subsets of tumor-associated macrophages (TAM) in tumors with the highest protumorigenesis signatures, highlighting their potential role in glioma progression. We also investigated the T-cell trajectory and identified the aryl hydrocarbon receptor (AHR) as a regulator of T-cell dysfunction, providing a potential target for glioma immunotherapy. We further demonstrated that knockout of AHR decreased chimeric antigen receptor (CAR) T-cell exhaustion and improved CAR T-cell antitumor efficacy both in vitro and in vivo. Finally, we explored intercellular communication mediated by ligand–receptor interactions within the tumor microenvironment and PBMCs and revealed the unique cellular interactions present in the tumor microenvironment. Taken together, our study provides a comprehensive immune landscape of IDH-WT high-grade gliomas and offers potential drug targets for glioma immunotherapy.
- 2 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH–Wild-Type High-Grade Gliomas
Isocitrate dehydrogenase (IDH)–wild-type (WT) high-grade gliomas, especially glioblastomas, are highly aggressive and have an immunosuppressive tumor microenvironment. Although tumor-infiltrating immune cells are known to play a critical role in glioma genesis, their heterogeneity and intercellular interactions remain poorly understood. In this study, we constructed a single-cell transcriptome landscape of immune cells from tumor tissue and matching peripheral blood mononuclear cells (PBMC) from IDH-WT high-grade glioma patients. Our analysis identified two subsets of tumor-associated macrophages (TAM) in tumors with the highest protumorigenesis signatures, highlighting their potential role in glioma progression. We also investigated the T-cell trajectory and identified the aryl hydrocarbon receptor (AHR) as a regulator of T-cell dysfunction, providing a potential target for glioma immunotherapy. We further demonstrated that knockout of AHR decreased chimeric antigen receptor (CAR) T-cell exhaustion and improved CAR T-cell antitumor efficacy both in vitro and in vivo. Finally, we explored intercellular communication mediated by ligand–receptor interactions within the tumor microenvironment and PBMCs and revealed the unique cellular interactions present in the tumor microenvironment. Taken together, our study provides a comprehensive immune landscape of IDH-WT high-grade gliomas and offers potential drug targets for glioma immunotherapy.